Eli Lilly Acquires SiteOne Therapeutics

Eli Lilly Acquires 4E Therapeutics

June 16, 2026

Pharmaceuticals

Eli Lilly and Company acquired Austin-based neuroscience company 4E Therapeutics to advance its non-opioid chronic pain pipeline. 4E is developing orally available MNK inhibitors targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, including lead candidate 4ET1103 that entered human Phase 1 trials with a favorable safety profile.

Eli Lilly and Company to Acquire Ajax Therapeutics, Inc.

April 27, 2026

Pharmaceuticals

Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. in a deal valued at up to $2.3 billion, including upfront and milestone-based payments. The acquisition is intended to expand Lilly’s oncology pipeline with Ajax’s lead candidate, AJ1-11095, a Type II JAK2 inhibitor in Phase 1 development for myelofibrosis, including patients previously treated with Type I JAK2 inhibitors.

Eli Lilly Acquires Orna Therapeutics in Up to $2.4 Billion Deal

February 9, 2026

Biotechnology

Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics, valuing the deal at up to $2.4 billion. The acquisition is intended to expand Lilly’s genetic medicine and in vivo cell engineering capabilities, particularly for advancing in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle (LNP) platform.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

JanOne Inc. Agrees to Acquire Soin Therapeutics LLC

September 16, 2022

Pharmaceuticals

JanOne Inc. has executed a term sheet to acquire Soin Therapeutics LLC and its patent-pending low-dose naltrexone formulation (to be named JAN123) for the treatment of Complex Regional Pain Syndrome (CRPS). The deal is valued at $13 million up front with up to $17 million in additional contingent payments (total up to $30 million); JanOne expects to advance JAN123 into GMP manufacturing and file an IND in 2023.